Briacell Therapeutics Corp Stock Price, News & Analysis

BriaCell Therapeutics (Nasdaq: BCTX) will present positive survival data for its Bria-IMT™ plus immune checkpoint inhibitor combination therapy in metastatic breast cancer at SABCS® 2024. The Phase 2 study showed a median overall survival of 13.4 months, exceeding historical controls, with final calculations pending as many patients remain alive. The therapy demonstrated promising results across all breast cancer subtypes, with a 9.5% objective response rate and 55% clinical benefit rate. The study included 54 patients total, with positive outcomes observed in patients with low circulating tumor cell counts and positive delayed type hypersensitivity responses.

BriaCell Therapeutics, a clinical-stage biotechnology company specializing in immunotherapies for cancer, has announced the resignation of Mr. Marc Lustig from its Board of Directors. The resignation is effective immediately. The company expressed gratitude for Mr. Lustig's significant contributions during his tenure.

BriaCell Therapeutics (NASDAQ: BCTX) has initiated dosing in its Phase 1/2 study of Bria-OTS™, a personalized next-generation immunotherapy for metastatic breast cancer. The study will evaluate Bria-OTS™ both as a standalone treatment and in combination with BeiGene's tislelizumab®. This therapy is an enhanced version of Bria-IMT™, which is currently in Phase 3 trials. The clinical trial targets patients with metastatic or locally recurrent breast cancer who have failed at least two prior systemic therapies. The company also plans to evaluate Bria-OTS+™, an advanced version, for prostate and other cancers.

BriaCell Therapeutics presented preclinical data showing strong anti-cancer activity of its next-generation immunotherapies, Bria-BRES+™ and Bria-PROS+™, at the 2024 SITC Conference. Both candidates effectively activated key components of the innate immune system and demonstrated ability to destroy breast and prostate cancer cells in preclinical models. The therapies are part of the Bria-OTS+™ platform, which represents an advancement in personalized, off-the-shelf cell-based immunotherapy. The company is currently conducting a Phase 1/2 study of first-generation Bria-OTS™ in metastatic breast cancer, with next-generation products expected to enter clinical trials in 1H2025.

BriaCell Therapeutics (Nasdaq: BCTX) announces five poster presentations, including a Spotlight poster, at the 2024 San Antonio Breast Cancer Symposium®. The presentations will showcase updated survival data and key biomarker findings from their Phase 2 trial of Bria-IMT™ plus immune checkpoint inhibitor in metastatic breast cancer. The presentations will also detail their planned Phase 3 study design for expanding Bria-IMT™ + CPI treatment to cancer patients with central nervous system metastases. The symposium will be held December 10-13, 2024, in San Antonio, Texas.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, TSX: BCT) reports positive survival data from its Phase 2 metastatic breast cancer (MBC) study. 55% of patients treated with Bria-IMT™ remained alive one year after enrollment, surpassing the survival rate of current standard care. The study included heavily pre-treated patients who had failed previous therapies, including checkpoint inhibitors and antibody-drug conjugates.

Notable outcomes include:

• Patient with 25 months overall survival (OS) after failing 6 prior treatments
• Patient with 24 months OS and stable disease
• Patient with 15 months OS after 7 prior therapy lines
• Patient with 14 months OS and 100% resolution of brain metastasis

BriaCell Therapeutics Corp. (NASDAQ: BCTX, TSX: BCT) has provided an update on its pivotal Phase 3 study of Bria-IMT™ in combination with an immune checkpoint inhibitor for metastatic breast cancer (MBC). Key points include:

- 35 clinical sites are actively enrolling patients
- The study will enroll up to 354 patients
- Primary endpoint is overall survival (OS)
- Interim data analysis planned at 144 events (deaths)
- Patient enrollment completion expected by mid-2025
- No serious adverse events related to Bria-IMT™ reported to date

Positive results could lead to full approval and marketing authorization for Bria-IMT™ in MBC patients. The Bria-IMT™ combination regimen has received FDA Fast Track designation.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) has closed its previously announced best-efforts offering of 5,128,500 common shares and warrants. The offering was priced at $0.975 per share and associated warrant, at-the-market under Nasdaq rules. The warrants have an exercise price of $0.85 per share and are immediately exercisable for five years. The offering raised approximately $5 million in gross proceeds.

The company plans to use the net proceeds for working capital requirements, general corporate purposes, and advancing business objectives. ThinkEquity acted as the sole placement agent for the offering. The securities were offered under BriaCell's effective shelf registration statement on Form S-3, with a prospectus supplement and prospectus filed with the SEC.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) has announced a $5 million offering of 5,128,500 common shares and warrants. The offering is priced at $0.975 per share and associated warrant, at-the-market under Nasdaq rules. The warrants have an exercise price of $0.85 per share and will be immediately exercisable for five years upon issuance.

The offering is expected to close on October 2, 2024, subject to customary closing conditions. ThinkEquity is acting as the sole placement agent. BriaCell intends to use the net proceeds for working capital requirements, general corporate purposes, and advancing business objectives. The offering is made pursuant to a shelf registration statement on Form S-3 filed with the SEC.